RMD

ResMed
D

RMD

Arincen97/100B

ResMed total debt 1993–2027

ResMed's total debt was 610.58M USD on 30 September 2026, down 27.9% on a year before. At the end of fiscal year 2026 it was 825.92M USD.

Last updated 6 Nov 2026 · Next report 28 Jan 2027

Total debt

Growth

Fiscal yearPeriod endingTotal debtGrowthCash and short-term investmentsNet cashDebt to equity
Latest quarter30 Sept 2026610.58M-27.86%1.01B400.16M0.10
FY202630 Jun 2026825.92M-3.04%1.47B643.32M0.13
FY202530 Jun 2025851.81M-2.53%1.21B357.64M0.14
FY202430 Jun 2024873.94M-44.68%238.36M-635.57M0.18
FY202330 Jun 20231.58B+72.19%227.89M-1.35B0.38
FY202230 Jun 2022917.55M+15.60%273.71M-643.84M0.27
FY202130 Jun 2021793.72M-38.91%295.28M-498.44M0.28
FY202030 Jun 20201.30B+2.24%463.16M-836.11M0.52
FY201930 Jun 20191.27B+351.53%147.13M-1.12B0.61
FY201830 Jun 2018281.45M-73.91%188.70M-92.75M0.14
FY201730 Jun 20171.08B-8.03%821.94M-256.68M0.55
FY201630 Jun 20161.17B+290.15%731.43M-441.34M0.69
FY201530 Jun 2015300.59M-0.06%717.25M416.66M0.19
FY201430 Jun 2014300.79M+0.00%905.73M604.94M0.17
FY201330 Jun 2013300.79M+19.91%876.05M575.26M0.19
FY201230 Jun 2012250.84M+150.43%809.54M558.71M0.16
FY201130 Jun 2011100.16M-17.69%735.27M635.10M0.06
FY201030 Jun 2010121.69M-24.76%488.78M367.09M0.09
FY200930 Jun 2009161.74M+17.49%415.65M253.91M0.15
FY200830 Jun 2008137.65M+18.67%321.08M183.42M0.13
FY200730 Jun 2007116.00M-4.20%277.74M161.74M0.12
FY200630 Jun 2006121.08M-30.56%219.54M98.46M0.16
FY200530 Jun 2005174.37M+53.97%142.19M-32.18M0.37
FY200430 Jun 2004113.25M0.00%140.93M27.68M0.31
FY200330 Jun 2003113.25M-8.11%121.02M7.77M0.40
FY200230 Jun 2002123.25M-17.83%92.84M-30.41M0.64
FY200130 Jun 2001150.00M—102.75M-47.25M1.49
FY200030 Jun 20000.00—21.96M21.96M0.00
FY199930 Jun 19990.00-100.00%16.70M16.70M0.00
FY199830 Jun 1998200.00K-66.67%15.50M15.30M0.00
FY199730 Jun 1997600.00K-33.33%9.10M8.50M0.01
FY199630 Jun 1996900.00K+12.50%5.50M4.60M0.02
FY199530 Jun 1995800.00K+100.00%3.30M2.50M0.03
FY199430 Jun 1994400.00K+33.33%3.70M3.30M0.07
FY199330 Jun 1993300.00K—1.70M1.40M0.10

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Total debt counts commercial paper, term debt and lease liabilities.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Free cash flow,Stock buybacks,Balance sheet

Common questions about ResMed's debt

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.